Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries

Thierry Pierre Robert Burnouf, Hadi Alphonse Goubran, M. Radosevich, Magdy El-Ekiaby

Research output: Contribution to journalArticle

Abstract

Non‐virally inactivated cryoprecipitate prepared by blood banks is still used in many countries, especially in the developing world, for the treatment of bleeding disorders due to factor VIII (FVIII), von Willebrand factor (VWF), or fibrinogen deficiency. As a consequence, patients receiving cryoprecipitate are at high risk of being infected by plasma‐borne viruses, such as HIV, and hepatitis B virus (HBV) or C virus (HCV). It is therefore urgent to develop easy‐to‐use, affordable and efficient methods for the viral inactivation of cryoprecipitate under conditions that ensure good maintenance of its haemostatic properties. Preparation of cryoprecipitate from large‐pool solvent‐detergent (SD) plasma seems not economically or technically feasible in developing countries. Cryoprecipitate prepared from single‐donor plasma virally inactivated by methylene‐blue/illumination has significantly reduced content of factor VIII and fibrinogen. There are no data on the quality of cryoprecipitate produced from plasma virally inactivated by techniques in development such as S‐51 psoralen/UV irradiation or by riboflavin/UV irradiation, but loss of FVIII and fibrinogen is reported in S‐51/UV‐treated plasma. Dry‐heat treatments of smallpool cryoprecipitate or intermediate‐purity factor VIII have been developed for use by blood banks, but they are not much used and some have not stopped the risk of transmission of HCV. Recently, a mini‐pool process and a closed bag system to perform SD treatment of cryoprecipitate have been developed for use by blood banks. Recovery of factor VIII, VWF, and fibrinogen is over 95%. Viral validation studies revealed reduction factors of > 4·17, > 4·73, and > 4·72 for HIV, BVDV, and PRV, respectively, within a few minutes of treatment. The SD bag system is in the process of CE‐marking and field testing should start in the near future.
Original languageEnglish
JournalISBT Science Series
Publication statusPublished - Oct 1 2007
Externally publishedYes

Fingerprint

Virus Inactivation
Blood Banks
Factor VIII
Fibrinogen
Viruses
Afibrinogenemia
HIV
Ficusin
von Willebrand Diseases
Riboflavin
Validation Studies
Hemostatics
Therapeutics
Hepatitis C
Lighting
Hepatitis B virus
Developing Countries
Maintenance
Hemorrhage
factor VIII, von Willebrand factor drug combination

Cite this

Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries. / Burnouf, Thierry Pierre Robert; Goubran, Hadi Alphonse; Radosevich, M.; El-Ekiaby, Magdy.

In: ISBT Science Series, 01.10.2007.

Research output: Contribution to journalArticle

@article{05f625e08e0842ef9f0d0e3c0318cb3c,
title = "Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries",
abstract = "Non‐virally inactivated cryoprecipitate prepared by blood banks is still used in many countries, especially in the developing world, for the treatment of bleeding disorders due to factor VIII (FVIII), von Willebrand factor (VWF), or fibrinogen deficiency. As a consequence, patients receiving cryoprecipitate are at high risk of being infected by plasma‐borne viruses, such as HIV, and hepatitis B virus (HBV) or C virus (HCV). It is therefore urgent to develop easy‐to‐use, affordable and efficient methods for the viral inactivation of cryoprecipitate under conditions that ensure good maintenance of its haemostatic properties. Preparation of cryoprecipitate from large‐pool solvent‐detergent (SD) plasma seems not economically or technically feasible in developing countries. Cryoprecipitate prepared from single‐donor plasma virally inactivated by methylene‐blue/illumination has significantly reduced content of factor VIII and fibrinogen. There are no data on the quality of cryoprecipitate produced from plasma virally inactivated by techniques in development such as S‐51 psoralen/UV irradiation or by riboflavin/UV irradiation, but loss of FVIII and fibrinogen is reported in S‐51/UV‐treated plasma. Dry‐heat treatments of smallpool cryoprecipitate or intermediate‐purity factor VIII have been developed for use by blood banks, but they are not much used and some have not stopped the risk of transmission of HCV. Recently, a mini‐pool process and a closed bag system to perform SD treatment of cryoprecipitate have been developed for use by blood banks. Recovery of factor VIII, VWF, and fibrinogen is over 95{\%}. Viral validation studies revealed reduction factors of > 4·17, > 4·73, and > 4·72 for HIV, BVDV, and PRV, respectively, within a few minutes of treatment. The SD bag system is in the process of CE‐marking and field testing should start in the near future.",
author = "Burnouf, {Thierry Pierre Robert} and Goubran, {Hadi Alphonse} and M. Radosevich and Magdy El-Ekiaby",
year = "2007",
month = "10",
day = "1",
language = "English",
journal = "ISBT Science Series",
issn = "1751-2816",
publisher = "John Wiley & Sons, Ltd (10.1111)",

}

TY - JOUR

T1 - Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries

AU - Burnouf, Thierry Pierre Robert

AU - Goubran, Hadi Alphonse

AU - Radosevich, M.

AU - El-Ekiaby, Magdy

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Non‐virally inactivated cryoprecipitate prepared by blood banks is still used in many countries, especially in the developing world, for the treatment of bleeding disorders due to factor VIII (FVIII), von Willebrand factor (VWF), or fibrinogen deficiency. As a consequence, patients receiving cryoprecipitate are at high risk of being infected by plasma‐borne viruses, such as HIV, and hepatitis B virus (HBV) or C virus (HCV). It is therefore urgent to develop easy‐to‐use, affordable and efficient methods for the viral inactivation of cryoprecipitate under conditions that ensure good maintenance of its haemostatic properties. Preparation of cryoprecipitate from large‐pool solvent‐detergent (SD) plasma seems not economically or technically feasible in developing countries. Cryoprecipitate prepared from single‐donor plasma virally inactivated by methylene‐blue/illumination has significantly reduced content of factor VIII and fibrinogen. There are no data on the quality of cryoprecipitate produced from plasma virally inactivated by techniques in development such as S‐51 psoralen/UV irradiation or by riboflavin/UV irradiation, but loss of FVIII and fibrinogen is reported in S‐51/UV‐treated plasma. Dry‐heat treatments of smallpool cryoprecipitate or intermediate‐purity factor VIII have been developed for use by blood banks, but they are not much used and some have not stopped the risk of transmission of HCV. Recently, a mini‐pool process and a closed bag system to perform SD treatment of cryoprecipitate have been developed for use by blood banks. Recovery of factor VIII, VWF, and fibrinogen is over 95%. Viral validation studies revealed reduction factors of > 4·17, > 4·73, and > 4·72 for HIV, BVDV, and PRV, respectively, within a few minutes of treatment. The SD bag system is in the process of CE‐marking and field testing should start in the near future.

AB - Non‐virally inactivated cryoprecipitate prepared by blood banks is still used in many countries, especially in the developing world, for the treatment of bleeding disorders due to factor VIII (FVIII), von Willebrand factor (VWF), or fibrinogen deficiency. As a consequence, patients receiving cryoprecipitate are at high risk of being infected by plasma‐borne viruses, such as HIV, and hepatitis B virus (HBV) or C virus (HCV). It is therefore urgent to develop easy‐to‐use, affordable and efficient methods for the viral inactivation of cryoprecipitate under conditions that ensure good maintenance of its haemostatic properties. Preparation of cryoprecipitate from large‐pool solvent‐detergent (SD) plasma seems not economically or technically feasible in developing countries. Cryoprecipitate prepared from single‐donor plasma virally inactivated by methylene‐blue/illumination has significantly reduced content of factor VIII and fibrinogen. There are no data on the quality of cryoprecipitate produced from plasma virally inactivated by techniques in development such as S‐51 psoralen/UV irradiation or by riboflavin/UV irradiation, but loss of FVIII and fibrinogen is reported in S‐51/UV‐treated plasma. Dry‐heat treatments of smallpool cryoprecipitate or intermediate‐purity factor VIII have been developed for use by blood banks, but they are not much used and some have not stopped the risk of transmission of HCV. Recently, a mini‐pool process and a closed bag system to perform SD treatment of cryoprecipitate have been developed for use by blood banks. Recovery of factor VIII, VWF, and fibrinogen is over 95%. Viral validation studies revealed reduction factors of > 4·17, > 4·73, and > 4·72 for HIV, BVDV, and PRV, respectively, within a few minutes of treatment. The SD bag system is in the process of CE‐marking and field testing should start in the near future.

M3 - Article

JO - ISBT Science Series

JF - ISBT Science Series

SN - 1751-2816

ER -